An update on naltrexone/bupropion extended-release in the treatment of obesity

References

• Flegal KM, Kruszon-Moran D, Carroll MD, et al. Trends in obesity among adults in the United States, 2005 to 2014. JAMA. 2016;315(21):2284–2291.
   PubMed Web of Science ®Google Scholar
• Zylke JW, Bauchner H. The unrelenting challenge of obesity. JAMA. 2016;315(21):2277–2278.
   PubMed Web of Science ®Google Scholar
• Finkelstein EA, Trogdon JG, Cohen JW, et al. Annual medical spending attributable to obesity: payer-and service-specific estimates. Health Aff (Millwood). 2009;28(5):w822–31.
   PubMed Web of Science ®Google Scholar
• Magkos F, Fraterrigo G, Yoshino J. Effects of moderate and subsequent progressive weight loss on metabolic function and adipose tissue biology in humans with obesity. Cell Metab. 2016;S1550–4131(16):30053–30055.
   Google Scholar
• Wing RR, Lang W, Wadden TA, et al. Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes. Diabetes Care. 2011;34(7):1481–1486.
   PubMed Web of Science ®Google Scholar
• Hinkle W, Cordell M, Leibel R, et al. Effects of reduced weight maintenance and leptin repletion on functional connectivity of the hypothalamus in obese humans. PLoS One. 2013;8(3):e59114.
   PubMed Web of Science ®Google Scholar
• Rosenbaum M, Hirsch J, Gallagher DA, et al. Long-term persistence of adaptive thermogenesis in subjects who have maintained a reduced body weight. Am J Clin Nutr. 2008;88(4):906–912.
   PubMed Web of Science ®Google Scholar
• Rosenbaum M, Goldsmith R, Bloomfield D. Low-dose leptin reverses skeletal muscle, autonomic, and neuroendocrine adaptations to maintenance of reduced weight. J Clin Invest. 2005;115(12):3579–3586.
   PubMed Web of Science ®Google Scholar
• Jensen MD, Ryan DH, Apovian CM, et al. 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. J Am Coll Cardiol. 2014;63(25Pt B):2985–3023.
   PubMed Web of Science ®Google Scholar
• Apovian CM, Aronne LJ, Bessesen DH, et al. Pharmacological management of obesity: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2015;100(2):342–362.
   PubMed Web of Science ®Google Scholar
• Greenway FL, Whitehouse MJ, Guttadauria M, et al. Rational design of a combination medication for the treatment of obesity. Obesity (Silver Spring). 2009;17(1):30–39.
   PubMed Web of Science ®Google Scholar
• Billes SK, Greenway FL. Combination therapy with naltrexone and bupropion for obesity. Expert Opin Pharmacother. 2011;12(11):1813–1826.
   PubMed Web of Science ®Google Scholar
• Billes SK, Sinnayah P, Cowley MA. Naltrexone/bupropion for obesity: an investigational combination pharmacotherapy for weight loss. Pharmacol Res. 2014;84:1–11.
   PubMed Web of Science ®Google Scholar
• Greenway FL, Dunayevich E, Tollefson G, et al. Comparison of combined bupropion and naltrexone therapy for obesity with monotherapy and placebo. J Clin Endocrinol Metab. 2009;94(12):4898–4906.
   PubMed Web of Science ®Google Scholar
• Greenway FL, Fujioka K, Plodkowski RA, et al. Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2010;376(9741):595–605.
   PubMed Web of Science ®Google Scholar
• Apovian CM, Aronne L, Rubino D, et al. A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II). Obesity (Silver Spring). 2013;21(5):935–943.
   PubMed Web of Science ®Google Scholar
• Wadden TA, Foreyt JP, Foster GD, et al. Weight loss with naltrexone SR/bupropion SR combination therapy as an adjunct to behavior modification: the COR-BMOD trial. Obesity (Silver Spring). 2011;19(1):110–120.
   PubMed Web of Science ®Google Scholar
• Hollander P, Gupta AK, Plodkowski R, et al. Effects of naltrexone sustained-release/bupropion sustained-release combination therapy on body weight and glycemic parameters in overweight and obese patients with type 2 diabetes. Diabetes Care. 2013;36(12):4022–4029.
   PubMed Web of Science ®Google Scholar
• Saunders KH, Shukla AP, Igel LI, et al. Pharmacotherapy for obesity. Endocrinol Metab Clin North Am. 2016;45(3):521–538.
   PubMed Web of Science ®Google Scholar
• Saunders KH, Kumar RB, Igel LI, et al. Pharmacologic approaches to weight management: recent gains and shortfalls in combating obesity. Curr Atheroscler Rep. 2016;18(7):36.
   PubMed Web of Science ®Google Scholar
• Khera R, Murad MH, Chandar AK, et al. Association of pharmacological treatments for obesity with weight loss and adverse events: a systematic review and meta-analysis. JAMA. 2016;315(22):2424–2434.
   PubMed Web of Science ®Google Scholar
• Aronne LJ, Wadden TA, Peterson C, et al. Evaluation of phentermine and topiramate versus phentermine/topiramate extended-release in obese adults. Obesity (Silver Spring). 2013;21(11):2163–2171.
   PubMed Web of Science ®Google Scholar
• Torgerson JS, Hauptman J, Boldrin MN, et al. XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. Diabetes Care. 2004;27(1):155–161.
   PubMed Web of Science ®Google Scholar
• Allison DB, Gadde KM, Garvey WT, et al. Controlled-release phentermine/topiramate in severely obese adults: a randomized controlled trial (EQUIP). Obesity (Silver Spring). 2012;20(2):330–342.
   PubMed Web of Science ®Google Scholar
• Gadde KM, Allison DB, Ryan DH, et al. Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial. Lancet. 2011;377(9774):1341–1352.
   PubMed Web of Science ®Google Scholar
• Garvey WT, Ryan DH, Look M, et al. Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study. Am J Clin Nutr. 2012;95(2):297–308.
   PubMed Web of Science ®Google Scholar
• Smith SR, Weissman NJ, Anderson CM, et al. Multicenter, placebo-controlled trial of lorcaserin for weight management. N Engl J Med. 2010;363(3):245–256.
   PubMed Web of Science ®Google Scholar
• Fidler MC, Sanchez M, Raether B, et al. A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: the BLOSSOM trial. J Clin Endocrinol Metab. 2011;96(10):3067–3077.
   PubMed Web of Science ®Google Scholar
• O’Neil PM, Smith SR, Weissman NJ, et al. Randomized placebo-controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: the BLOOM-DM study. Obesity (Silver Spring). 2012;20(7):1426–1436.
   PubMed Web of Science ®Google Scholar
• Pi-Sunyer X, Astrup A, Fujioka K, et al. A randomized, controlled trial of 3.0 mg of liraglutide in weight management. N Engl J Med. 2015;373(1):11–22.
   PubMed Web of Science ®Google Scholar
• Davies MJ, Bergenstal R, Bode B, et al. Efficacy of liraglutide for weight loss among patients with type 2 diabetes: the SCALE diabetes randomized clinical trial. JAMA. 2015;314(7):687–699.
   PubMed Web of Science ®Google Scholar
• Wadden TA, Hollander P, Klein S, et al. Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: the SCALE maintenance randomized study. Int J Obes (Lond). 2013;37(11):1443–1451.
   PubMed Web of Science ®Google Scholar
• Smith SR, Garvey WT, Greenway F, et al. Combination weight management (WM) pharmacotherapy with lorcaserin (LOR) and immediate release (IR) phentermine (phen) [abstract]. Poster presented at Obesity Week; 2014 Nov 2–7; Boston (MA)
   Google Scholar
• Hollander PA, Bays HE, Rosenstock J, et al. Coadministration of canagliflozin (CANA) and phentermine (PHEN) for weight management in overweight and obese adults. [abstract]. Poster presented at American Diabetes Association Annual Meeting; 2016 Jun 10–14, New Orleans (LA)
   Google Scholar
• Contrave [package insert]. Deerfield (IL): Takeda Pharmaceuticals America, Inc; 2014.
   Google Scholar
• Revia [package insert]. Pomona (CA): Duramed Pharmaceuticals, Inc; 2013.
   Google Scholar
• Zyban [package insert]. Research Triangle Park (NC): GlaxoSmithKline; 2016.
   Google Scholar
• Digenio AG, Mancuso JP, Gerber RA, et al. Comparison of methods for delivering a lifestyle modification program for obese patients: a randomized trial. Ann Intern Med. 2009 Feb;150(4):255–262.
   PubMed Web of Science ®Google Scholar
• Wadden TA, Berkowitz RI, Womble LG, et al. Randomized trial of lifestyle modification and pharmacotherapy for obesity. N Engl J Med. 2005;353(20):2111–2120.
   PubMed Web of Science ®Google Scholar
• Cardiovascular outcomes study of naltrexone SR/bupropion SR in overweight and obese subjects with cardiovascular risk factors (the LIGHT study). ClinicalTrials.gov. 2012 [cited 2016 Jul 8]. Available from: https://clinicaltrials.gov/ct2/show/NCT01601704
   Google Scholar
• Nissen SE, Wolski KE, Prcela L, et al. Effect of naltrexone-bupropion on major adverse cardiovascular events in overweight and obese patients with cardiovascular risk factors: a randomized clinical trial. JAMA. 2016;315(10):990–1004.
   PubMed Web of Science ®Google Scholar
• Naltrexone/Bupropion Cardiovascular Outcomes Study ClinicalTrials.gov. 2015 [cited 2016 Jul 8]. Available from: https://clinicaltrials.gov/ct2/show/NCT02638129?term=contrave+cardiovascular&rank=1
   Google Scholar
• Stinton LM, Shaffer EA. Epidemiology of gallbladder disease: cholelithiasis and cancer. Gut Liver. 2012;6(2):172–187.
   PubMed Web of Science ®Google Scholar
• FDA approves weight-management drug Contrave. U.S. Food and Drug Administration. 2014 [cited 2016 July 9]. Available from: http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm413896.htm
   Google Scholar
• Thomas CE, Mauer EA, Shukla AP, et al. Low adoption of weight loss medications: a comparison of prescribing patterns of antiobesity pharmacotherapies and SGLT2s. Obesity (Silver Spring). 2016;24(9):1955–1961.
   PubMed Web of Science ®Google Scholar